AstraZeneca sets ambition to deliver $80 billion Total Revenue by …
May 21, 2024 · AstraZeneca’s ambitions, forecasts and targets in this announcement (the “Financial Ambition Statements”) are derived from AstraZeneca’s most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised.
AstraZeneca - Research-Based BioPharmaceutical Company
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Media Centre - AstraZeneca
Dec 4, 2024 · AstraZeneca Media centre. The Hub for our Articles, Press Releases and Webcasts & Presentations.
AstraZeneca China President currently under investigation
Oct 30, 2024 · Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities. Our China operations continue under the leadership of the current General Manager of AstraZeneca China.
9M and Q3 2023 results - AstraZeneca
Nov 9, 2023 · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company continued its strong growth trajectory in the third quarter with Total Revenue from our non‑COVID-19 medicines up 13% compared to last year.
AstraZeneca to acquire Fusion to accelerate the development of …
Mar 19, 2024 · AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer PUBLISHED 19 March 2024 Includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate
H1 and Q2 2024 results - AstraZeneca
Jul 25, 2024 · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 guidance for both Total Revenue and Core EPS.
AstraZeneca to acquire Icosavax, including potential first-in-class …
Dec 12, 2023 · The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12.
AstraZeneca completes equity investment agreement with Cellectis
May 6, 2024 · Post-closing of this second investment, AstraZeneca holds a total equity stake of c.44% in Cellectis. AstraZeneca expects to continue to treat its investment in Cellectis as an associate.
AstraZeneca advances science of infectious disease protection at …
Oct 16, 2024 · AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 13 th annual IDWeek in Los Angeles, California, from 16-19 October 2024. The Company will highlight progress in advancing novel immunisations against infectious diseases of high unmet need and share real-world evidence showing the burden of respiratory viral ...
- Some results have been removed
Skip to content